Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/27/2003US20030060428 Bicyclo (3.2.1)octane in a double ring system having a basic chemical skeletal of a kaurene structure that responds only at elevated plasma glucose concentrations
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030060397 Method of treating and preventing acute neural lesions with substances that modulate the expression or function of a protein involved in the cell cycle and pharmaceutical preparations containing such substances
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059874 Polypeptide for use in the treatment of autoimmune, inflammatatory, arthritic, atherosclerotic, allergenic, dermatitis, urticaria, adult respiratory distress syndrome, asthma, rhinitis, eczema and infections
03/27/2003US20030059869 Novel G protein-coupled receptor, GAVE3
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059856 Detection of modulator of receptor binding activity; obtain sample containing receptor, incubate with test agent and ligand, monitor binding activity of ligand, adjusment in binding activity indicates modulator
03/27/2003US20030059852 Detecting modulators of integrin activity; obtain sample containing integrin, incubate with test compound, monitor adjustment in integrin activity, adjustment in integrin activity indicates modulator
03/27/2003US20030059796 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis
03/27/2003US20030059470 Dispersions for the formulation of slightly or poorly soluble agents
03/27/2003US20030059467 A tablet core containing from 0.5 to 10% of doxazosin and 20 to 95% by weight of polyethylene oxide forming a hydrohilic matrix, and core being obtained by compressing granules
03/27/2003US20030059461 Molecular delivery vehicle for delivery of selected compounds to targets
03/27/2003US20030059454 Optimized dosing for drug coated stents
03/27/2003US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor
03/27/2003US20030059423 Method for treating symptoms of diabetes
03/27/2003US20030059420 Comprises catalytic or stoichiometric lipid removal, wherein proteins and/or polypeptides (lysosoymal acid lipase) target receptors in and/or on the cell which lead to uptake into the lysosome
03/27/2003US20030059417 Methods and compositions for diagnosing and treating disorders involving angiogenesis
03/27/2003US20030059414 Cell populations which co-express CD49c and CD90
03/27/2003CA2709442A1 Cell populations which co-express cd49c and cd90
03/27/2003CA2461073A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003CA2461072A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003CA2461071A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460719A1 Igf-binding protein-derived peptide or small molecule
03/27/2003CA2460440A1 Salicylic acid salts, processes for preparing them and their use as pharmaceutical compositions
03/27/2003CA2460358A1 Hydroxyfattysulfonic acid analogs
03/27/2003CA2460319A1 Lpa receptor agonists and antagonists and methods of use
03/27/2003CA2460263A1 Hydroxyeicosenoic acid analogs
03/27/2003CA2460150A1 Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis
03/27/2003CA2459773A1 Enamel matrix protein compositions for modulating immune response
03/27/2003CA2459454A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
03/27/2003CA2459140A1 Protein modification and maintenance molecules
03/27/2003CA2459022A1 Neurotransmission-associated proteins
03/27/2003CA2458720A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003CA2454023A1 Dna-pk inhibitors in the treatment of retroviral mediated diseases
03/27/2003CA2429005A1 Substituted benzoic acid derivatives having nf-kb inhibiting action
03/27/2003CA2423885A1 Thiazole and oxazole derivatives
03/26/2003WO2002026732A1 Benzodiazepine derivative
03/26/2003EP1296142A2 Calcium receptor active molecules
03/26/2003EP1296138A1 Use of disease-associated gene
03/26/2003EP1295939A1 Insulin-like growth factor binding protein
03/26/2003EP1295936A1 Method of preparing heart muscle cells and method of searching for remedy for heart diseases
03/26/2003EP1295875A1 Heterocyclic compounds
03/26/2003EP1295865A1 Novel dicarboxylic acid derivatives
03/26/2003EP1295603A1 The process of extracting from haw-pit by dry distillation and its device
03/26/2003EP1295596A1 Systems and compounds for drug delivery to interstitial regions of the myocardium
03/26/2003EP1294924A2 Method for identifying medically valuable active substances
03/26/2003EP1294901A2 Novel proteases
03/26/2003EP1294895A2 Calpain protease 12
03/26/2003EP1294887A1 Insulin homolog polypeptide zins4
03/26/2003EP1294885A2 B7-like molecules and uses thereof
03/26/2003EP1294882A2 B7-like molecules and uses thereof
03/26/2003EP1294874A2 Cd154 variants and uses thereof
03/26/2003EP1294868A2 Adenylyl and guanylyl cyclases
03/26/2003EP1294867A1 Human site-1 protease promoter
03/26/2003EP1294856A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294757A2 Glucagon-like peptide-1 analogs
03/26/2003EP1294752A2 Angiogenesis-modulating compositions and uses
03/26/2003EP1294746A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
03/26/2003EP1294741A2 Dipeptide inhibitors for the blood-clotting factor xa
03/26/2003EP1294740A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use
03/26/2003EP1294729A1 2-aminoalkyl-thieno[2,3-d]pyrimidines
03/26/2003EP1294728A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD
03/26/2003EP1294725A2 Multicyclic compounds and the use thereof as inhibitors of parp, vegfr2 and mlk3 enzymes
03/26/2003EP1294724A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
03/26/2003EP1294721A1 Cyclic gmp-specific phosphodiesterase inhibitors
03/26/2003EP1294718A2 6,5-fused bicyclic heterocycles
03/26/2003EP1294716A1 Lactam inhibitors of factor xa and method
03/26/2003EP1294714A2 Thrombin receptor antagonists
03/26/2003EP1294711A2 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as as modulators of protein kinases
03/26/2003EP1294707A2 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
03/26/2003EP1294704A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
03/26/2003EP1294701A2 Bis-arylsulfones
03/26/2003EP1294699A2 Modulators of tnf- alpha signalling
03/26/2003EP1294696A2 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
03/26/2003EP1294691A1 Serine protease inhibitors
03/26/2003EP1294690A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
03/26/2003EP1294689A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
03/26/2003EP1294688A2 Indolinone derivatives as protein kinase/phosphatase inhibitors
03/26/2003EP1294687A2 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
03/26/2003EP1294686A2 Indole derivatives and their use as 15-lipoxygenase inhibitors
03/26/2003EP1294681A2 Fmoc-l-leucine and derivatives thereof as ppar- gamma agonists
03/26/2003EP1294679A1 Beta-amino acid nitrile derivatives
03/26/2003EP1294439A2 Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system
03/26/2003EP1294409A2 Membrane-permeant peptide complexes for medical imaging
03/26/2003EP1294407A2 Dual recombinant gene therapy compositions and methods of use
03/26/2003EP1294395A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR
03/26/2003EP1294393A2 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment and diagnosis of athersclerosis
03/26/2003EP1294389A1 THERAPEUTICAL USE OF i SOPHORA FLAVESCENS /i OR i SOPHORA SUBPROSTRATA /i EXTRACTS
03/26/2003EP1294388A1 EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE
03/26/2003EP1294383A2 Oral compositions comprising antimicrobial agents
03/26/2003EP1294382A1 7-hydroxyepiandrosterone having neuroprotective activity
03/26/2003EP1294380A1 A method for treating septic shock
03/26/2003EP1294379A1 A new use for deferiprone
03/26/2003EP1294376A2 Medicament for combating respiratory depression
03/26/2003EP1294369A1 NOVEL FORMULATIONS OF $g(a)-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
03/26/2003EP1225810B1 Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
1 ... 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 ... 1595